MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from maturities
of marketable...
$243,337K
Proceeds from offerings
of common stock and...
$540K
Proceeds from issuance of
common stock upon...
$483K
Net cash provided by
(used in) investing...
$112,040K
Net cash provided by
financing activities
$1,023K
Canceled cashflow
$131,297K
Net increase
(decrease) in cash, cash...
$26,964K
Canceled cashflow
$86,099K
Purchases of marketable
securities
$131,247K
Purchases of property and
equipment
$50K
Stock-based compensation
expense
$10,399K
Impairment of long-lived
assets
$5,914K
Noncash lease expense
$4,206K
Depreciation and
amortization expense
$3,332K
Prepaid expenses and
other current assets
-$2,827K
Accrued expenses and
other liabilities
$2,204K
Accounts payable
$481K
Loss on disposal of
property and equipment
-$31K
Net cash used in
operating activities
-$86,099K
Canceled cashflow
$29,394K
Net loss
-$74,283K
Deferred revenue
-$30,909K
Operating lease
liabilities
-$6,743K
Accretion of discount on
marketable securities
$1,926K
Gain on lease
modification
$1,632K
Back
Back
Cash Flow
source: myfinsight.com
Foghorn Therapeutics Inc. (FHTX)
Foghorn Therapeutics Inc. (FHTX)